Brawn Biotech (BOM:530207) Cyclically Adjusted Revenue per Share: ₹152.28 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530207 Brawn Biotech Ltd BOM:530207
59 GF Score
Price ₹23.30
GF Value ₹21.89
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Brawn Biotech Cyclically Adjusted Revenue per Share?

Brawn Biotech BOM:530207 +0.04% 59 Cyclically Adjusted Revenue per Share is ₹152.28 as of Jun. 2026. GuruFocus rates BOM:530207 with a GF Score™ of 59/100 and a GF Value™ of ₹21.89 (Fairly Valued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Brawn Biotech's adjusted revenue per share for the three months ended in Jun. 2026 was ₹20.475. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹152.28 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Brawn Biotech's average Cyclically Adjusted Revenue Growth Rate was -8.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Brawn Biotech was 0.20% per year. The lowest was -5.50% per year. And the median was -2.30% per year.

As of today (2026-09-11), Brawn Biotech's current stock price is ₹23.30. Brawn Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹152.28. Brawn Biotech's Cyclically Adjusted PS Ratio of today is 0.15.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Brawn Biotech was 0.24. The lowest was 0.08. And the median was 0.12.


Brawn Biotech  (BOM:530207) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Brawn Biotech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=23.30/152.28
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Brawn Biotech was 0.24. The lowest was 0.08. And the median was 0.12.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Brawn Biotech Cyclically Adjusted Revenue per Share Related Terms


Brawn Biotech Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Brawn Biotech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brawn Biotech Cyclically Adjusted Revenue per Share Chart

Brawn Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 179.09 183.98 177.30 166.88 155.12

Brawn Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 166.21 163.95 159.68 155.12 152.28

BOM:530207 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Brawn Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brawn Biotech Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Brawn Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Brawn Biotech's Cyclically Adjusted PS Ratio falls into.


BOM:530207
59GF Score
Brawn Biotech Ltd BOM:530207
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brawn Biotech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Brawn Biotech's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=20.475/167.3573*167.3573
=20.475

Current CPI (Jun. 2026) = 167.3573.

Brawn Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 43.312 105.961 68.408
201612 54.391 105.196 86.531
201703 54.678 105.196 86.988
201706 36.478 107.109 56.997
201709 38.651 109.021 59.333
201712 50.099 109.404 76.637
201803 52.350 109.786 79.802
201806 49.823 111.317 74.906
201809 49.864 115.142 72.477
201812 70.779 115.142 102.876
201903 51.233 118.202 72.539
201906 59.492 120.880 82.366
201909 39.598 123.175 53.802
201912 44.076 126.235 58.434
202003 22.094 124.705 29.651
202006 24.774 127.000 32.646
202009 32.332 130.118 41.585
202012 49.274 130.889 63.003
202103 10.156 131.771 12.899
202106 3.760 134.084 4.693
202109 6.926 135.847 8.533
202112 8.426 138.161 10.207
202203 7.401 138.822 8.922
202206 11.151 142.347 13.110
202209 25.890 144.661 29.952
202212 21.030 145.763 24.146
202303 10.652 146.865 12.138
202306 24.518 150.280 27.304
202309 9.874 151.492 10.908
202312 9.454 152.924 10.346
202403 8.190 153.035 8.957
202406 14.082 155.789 15.128
202409 9.209 157.882 9.762
202412 12.820 158.323 13.552
202503 19.195 157.552 20.390
202506 21.862 159.755 22.902
202509 17.125 162.289 17.660
202512 14.724 163.281 15.092
202603 6.606 164.272 6.730
202606 20.475 167.357 20.475

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹152.28 mean?
Brawn Biotech (BOM:530207) has a Cyclically Adjusted Revenue per Share of ₹152.28 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Brawn Biotech and its competitors.
Is Brawn Biotech's Cyclically Adjusted Revenue per Share too high?
Brawn Biotech's current Cyclically Adjusted Revenue per Share is ₹152.28. Overall, Brawn Biotech has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Brawn Biotech's Cyclically Adjusted Revenue per Share compare to ZTS?
Brawn Biotech's Cyclically Adjusted Revenue per Share of ₹152.28 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Brawn Biotech and its competitors. Brawn Biotech's current Cyclically Adjusted Revenue per Share is ₹152.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brawn Biotech stock overvalued right now?
Based on GuruFocus' analysis, Brawn Biotech (BOM:530207) is currently considered Fairly Valued. The stock's GF Value™ is ₹21.89, compared to a current price of ₹23.30 — trading 6.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹152.28. Brawn Biotech's overall GF Score™ is 59/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Brawn Biotech (BOM:530207), the current Cyclically Adjusted Revenue per Share is ₹152.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Brawn Biotech (BOM:530207) Overvalued in 2026?

Based on GuruFocus' analysis, Brawn Biotech stock appears to be overvalued. The current stock price of ₹23.30 is trading 6.4% above its estimated GF Value™ of ₹21.89. GuruFocus considers Brawn Biotech to be Fairly Valued.

Key valuation signals for BOM:530207:

  • Cyclically Adjusted Revenue per Share: ₹152.28
  • GF Value™: ₹21.89 vs. price of ₹23.30 (6.4% above fair value)
  • GF Score™: 59/100 with 9 warning signs

No single metric tells the full story. See the BOM:530207 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Brawn Biotech Business Description

Address Lajpat Nagar-1, C-64, First Floor, New Delhi, IND, 110024
Brawn Biotech Ltd is a healthcare company. It is engaged in the business activity of wholesale of pharmaceutical and medical goods. The company's pharmaceutical goods cover product segments like Antibacterial, Cardiovascular, Anti-diabetic, Analgesics, Gastrointestinal, Antifungals, Skin Care, Antipsychotics, Anti-asthmatic, Antacids, Antimalarial, and Nutritionals.
59GF Score

Get the complete analysis for BOM:530207

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹23.30
Price
₹21.89
GF Value